Endologix, Inc. (NASDAQ: ELGX) is one of the best known developers and marketers of unique treatments for aortic disorders. The company recently announced that the first two patients with abdominal aortic aneurysms (AAA) were treated with the Ovation Alto™ Abdominal Stent Graft System in Auckland, New Zealand. Andrew Hill, MD, and Andrew Holden, MD, of Auckland City Hospital treated the two patients.
Ovation Alto is part of the abdominal graft systems. The device was introduced to the market very recently and has been added to the Ovation® platform. Patients with complicated AAAs have been added to the Ovation Alto, expanding Endovascular Aneurysm Repair (EVAR) treatment. Specifically, the treatment is targeted at patients with a very short aorta or those who are suffering with aortic neck anatomy. Patients can now be treated with the comfortable O-rings made of CustomSeal™ polymer, which are placed near the top of the endograft and act as a seal underneath the renal arteries.
In a news release, Bob Mitchell, president of Endologix, said, “The first patients treated with the Ovation Alto system is a significant milestone for our new product strategy. It further enhances our leadership position in the development of unique sealing technologies for the treatment of AAA and broadens our product portfolio to address a wide range of anatomies, including the underserved complex AAA market. We would like to thank Dr. Holden and Dr. Hill for their collaboration in the first patients treated with the Ovation Alto system.”
Ovation Alto showed incredible results, especially in the Ovation global pivotal trial, with a count of 501-patient European Post-Market Registry. The Ovation platform has been successful in treating around 10,000 patients globally so far. This is the lowest profile FDA-approved EVAR device. The Ovation Alto has not been accepted in any market as of yet. However, it is expected to be introduced to the U.S. in 2018, and Europe in 2017.
Dr. Andrew Hill added, “The Ovation Alto system has the potential to increase the number of AAA patients treated with EVAR due to its unique sealing technology and ultra-low profile design. The new system is designed to provide the broadest indications of all infrarenal EVAR devices, which represents an important advancement for physicians and their AAA patients.”
Dr. Holde continued, “The repositioned sealing ring in the Ovation Alto system expands the EVAR treatment of AAA patients to include short and challenging aortic necks, which represents a significant segment of the underserved complex AAA market. We are pleased to be the first center in the world to implant Ovation Alto and look forward to treating more patients and sharing our experience with the clinical community.”
For more information, visit www.Endologix.com
About NetworkNewsWire
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing network of more than 5,000 key distribution outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge. For more information, visit www.networknewswire.com.
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.net
